Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Hot on Facebook
Uproar After NC State Agent 'Fixes' Girl's Lunch Preschooler has to eat chicken nuggets instead of mom's meal »

NEWS ABOUT: pharmaceutical companies

Big Pharma Sickens Universities

It's too easy for drug companies to skirt lax academic regulations

(Newser) - Weak legislation allows professors to collect huge under-the-table payments from Big Pharma, and it’s time to fight back, Dan Greenberg writes in the Chronicle of Higher Education. Pharmaceutical companies pay professors to shill drugs and lend their names to industry research, and the only oversight is an honor-system mechanism... More »

Deal Delays Generic Lipitor Until 2011

Pact with Indian drug maker stands to net billions for Pfizer

(Newser) - Pfizer has struck a deal with an Indian generic drug maker to delay a cheaper version of Lipitor in the US until November 2011. The agreement limiting generic versions of the cholesterol-lowering drug will translate into billions more in profits for Pfizer, the New York Times reports. Lipitor, the world's... More »

Deadly Heparin Found in 11 Nations

FDA traces tainted Chinese blood thinner that killed 81

(Newser) - The FDA has traced a contaminated blood thinner from a Chinese factory to 11 countries, the New York Times reports. Severe reactions to the contaminated heparin have been linked to the deaths of 81 Americans, but it wasn't immediately clear if the drug may have triggered fatalities in other countries.... More »

Merck Used Ghostwriters to Draft Rosy Vioxx Studies

Company downplayed risks in medical articles on drug found to be a killer

(Newser) - Merck used its own ghostwriters to draft articles minimizing risks of its drug Vioxx, then found medical researchers to lend their names to the research, the Wall Street Journal reports. Merck, which pulled the painkiller from shelves four years ago over heart-attack risks, rejects the claims as "misleading."... More »

Doc: Merck Fudged Minutes of Meeting

Vytorin probe challeges firm's account of delay in trial results

(Newser) - Merck's "minutes" of a meeting of heart doctors discussing cholesterol drug Vytorin were created a month after the meeting and distorted the viewpoints of the experts, one panel member changes. The drug company submitted the document to congressional investigators probing its two-year delay in releasing a report saying the... More »

Feds ID Extra Drug in Baxter's Recalled Heparin

FDA unsure if chemical was behind reactions to blood-thinner

(Newser) - The Food and Drug Administration has identified the extra ingredient found in samples of Baxter’s blood-thinning drug heparin, the Wall Street Journal reports today. Some batches of the drug—recalled in January after reports of allergic reactions—contained over-sulfated chondroitin sulfate, but it is not certain that was the... More »

Heparin Supply Chain Shaky in China

Troubles could trace back to vulnerable raw materials

(Newser) - With at least four US patients dead and hundreds suffering complications from the blood-thinning drug heparin, the New York Times follows the supply chain back to Chinese slaughterhouses that deal with the pig intestines that provide raw material for the drug. Though companies say the chain is secure, the Times... More »

Pfizer Pulls Lipitor Ads After Probe

Critics accused pharma giant of inflating doctor's CV

(Newser) - Pfizer said today it will drop its ads for cholesterol drug Lipitor due to criticisms of the TV spots, the New York Times reports. US lawmakers recently probed whether the campaign had inflated the credentials of artificial heart developer Dr. Robert Jarvik. "The way in which we presented Dr.... More »

Vaccines, Medicines to Treat Addiction on the Way

Many resist pharmaceutical approach

(Newser) - It's been decades since scientists recognized that addiction is a disease, not just a lack of willpower, but only now are potential treatments coming online that address what Newsweek calls "a chronic, relapsing brain disorder to be managed with all the tools at medicine's disposal." The magazine surveys... More »

FDA Delay Cost 22,000 Lives: Doctor

Agency took a year to pull lethal heart surgery drug Trasylol

(Newser) - A prominent researcher who revealed widespread fatalities associated with the heart surgery drug Trasylol says 22,000 people died because of the FDA's delay in blowing the whistle on the drug after his study was published. Drugmaker Bayer also failed to disclose negative results of its own study. In a... More »

Merck Will Pay $650M to End Discount Probes

Drug company alleged to have kept Medicaid in dark on lowest prices

(Newser) - Drug company Merck will dish out $650 million to resolve lawsuits and probes into marketing schemes, the Wall Street Journal reports. Central to the investigations is the company’s “nominal pricing,” which slashed some drug prices by 90% for hospitals but hid the discounts from Medicaid, even though... More »

Eli Lilly Could Pay $1B Settlement

Fine for illegally promoting antipsychotic drug Zyprexa would be biggest ever

(Newser) - Drug-maker Eli Lilly could pay more than $1 billion to state and federal authorities to settle an investigation into how the company marketed an antipsychotic drug, the New York Times reports. In 2000-03, Lilly pushed doctors to prescribe Zyprexa as a treatment for age-related dementia—though the drug is approved... More »

Antidepressant Studies Distort Drugs' Usefulness

New study says negative reports often go unpublished

(Newser) - Roughly half of the medical studies involving antidepressants that found little or no effect on patients have gone unpublished or had their findings mischaracterized as positive, a new study reveals. The emphasis on publishing only studies with glowing reviews gives patients and doctors a false sense of the effectiveness of... More »

Merck May Pay $700M for Schizophrenia Drug

Pharma giant restocks pipeline by snapping up Swiss psychotherapy

(Newser) - Merck today finalized a deal worth as much as $700 million to license a schizophrenia drug from Swiss biotech firm Addex Pharmaceuticals. Addex will get $22 million up front, and qualify for another $680 million in milestone payments. Such licensing deals are growing commonplace, Reuters reports, as big pharma turns... More »

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic... More »

Bristol-Myers to Slash Jobs, Shut Plants

Drugmaker shrinks, says expiring patents will cut profits

(Newser) - Bristol-Myers Squibb said today it will lay off 10% of its work force—totaling 4,300 jobs—and close or sell half its 27 factories in a plan to save $1.5 billion by 2010, the Wall Street Journal reports. The firm also will sell its medical-imaging division and possibly... More »

Lack of Info Plagues Docs Treating Kids

Limited funding for research on meds puts children at risk

(Newser) - A dearth of information on the effects of prescription drugs on children is putting millions of kids at risk, the Washington Post reports. Two-thirds of the medications prescribed to kids haven't been tested on them, and those that have been tested often produce unexpected results: A migraine drug that works... More »

Big Pharma Goes East to Test Drugs

Low costs lure R&D, but critics doubt product safety

(Newser) - Big Pharma is testing more drugs in China, where studies cost less and a big, aging population has more chronic ailments, Time reports. But critics question the country's product safety and ponder the fate of tested patients. Even Big Pharma is concerned—about intellectual property rights—but the lure of... More »

Battle Brews in Pharma's Market

Pfizer launches attack on generic drug that threatens Lipitor's dominance

(Newser) - Pfizer is trying to stave off its own heart attack now that its flagship cholesterol-lowering drug Lipitor faces stiff competition from a cheaper generic. Lipitor is still patent-protected, but a very similar drug called Zocor isn't, and since a generic version called simvastatin hit the market, many doctors and insurers... More »

More Docs Just Say No to Pharma Reps

Barrage of visits, free samples may cloud prescribing practices

(Newser) - More doctors, hospitals, and medical schools are limiting or barring visits from drug-company reps as the calls become more frequent and concerns grow that they may influence prescribing. An organization of doctors who pledge not to welcome pharma reps has only 800 members, but institutional players—including some states—are... More »

Stories 41 - 60 | << Prev   Next >>
NEWS FROM OUR PARTNERS
Other Sites We Like:   24/7 Wall St.   |   Betty Confidential   |   BuzzFeed   |   Cracked   |   Fark   |   Timelines   |   The Frisky   |   Geek Sugar   |   NewsOne